COVID: Existing vaccines will be less effective against Omicron, according to Moderna boss (FT)

COVID: existing vaccines will be less effective against Omicron, according to the boss of Moderna (FT)

MISE & Agrave; DAY

Hong Kong | Existing COVID-19 vaccines will be less effective against the Omicron variant and it will take several months to develop a new vaccine, the boss of the US pharmaceutical company Moderna said in an interview published in the Financial Times Tuesday. . & nbsp;

Stéphane Bancel believes that there will be a “significant drop” in the effectiveness of vaccines. “All the scientists I spoke to (…) say 'this is not going to do it'”, according to him. & Nbsp;

He indicated to the daily that data on the effectiveness current vaccines will be available within the next two weeks. & nbsp;

This warning from Mr. Bancel comes as G7 health ministers urgently met to discuss this new variant that is spreading across the planet and new countries have decided to close their borders again. & Nbsp ;

The World Health Organization (WHO) considers that this new variant of the coronavirus presents “a very high risk” at the global level.

Mr. Bancel explained that the researchers are worried because 32 of the 50 mutations found in the Omicron variant are found in the spike protein, the key to the virus entering the body. & Nbsp;

According to him, the vaccine current will not have “the same level of efficacy as we had against the Delta variant.” & nbsp;

Moderna has already announced its intention to develop a specific booster dose for this new variant, just like the American laboratory Pfizer. & nbsp;

The laboratory boss estimated that his company is able to provide between 2 and 3 billion doses in 2022, but that it would be dangerous to direct all production towards a vaccine specific to the Omicron variant while other strains of the virus are still circulating. & nbsp;

Share Button